Metformin and Diurnal Variation in Maximal Fat Oxidation in Metabolic Syndrome

Metformin and Diurnal Variation in Maximal Fat Oxidation During Exercise in Patients With Metabolic Syndrome: A Randomized Crossover Trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202510506789089

Enrollment

Registered

2025-10-22

Start date

2025-10-21

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine

Interventions

morning condition without metformin

Morning condition with metformin

Afternoon Without Metformin

Afternoon with metformin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Increased waist circumference (=102 cm in men; =88 cm in women) Elevated triglycerides (=150 mg/dl), or on medication for treating the condition Reduced HDL-cholesterol (<40mg/dl in men, <50 mg/dl in women), or on medication for treating the condition High blood pressure (=130 mmHg systolic or =85mmHg diastolic), or on medication for treating the condition Elevated fasting glucose (=100 mg/dl), or on medication for treating the condition

Exclusion criteria

Exclusion criteria: Any condition that counter-indicate exercise Patients under glucose lowering agents

Design outcomes

Primary

Measure	Time frame
Maximal Fat Oxidation;Fatmax	—

Secondary

Measure	Time frame
Glucose ;Insulin;Energy expenditure;VO2peak	—

Countries

Tunisia

Contacts

Public ContactJabeur Methnani

Postdoctoral researcher

jabeur.methnani@gmail.com+21693201456

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026